JACC:外周动脉疾病预示心肌梗塞合并心源性休克患者不良结局

2022-04-05 网络 网络

在出现AMI和CS的患者中,PAD与较差的肢体结果和生存率有关

急性心肌梗死(AMI)所致的心源性休克(CS)是心梗患者主要死亡因素之一,其中主要的发病机制为急性心肌梗死后引起急性左右心衰竭、周围血管阻力改变、重要器官供血不足,引发炎性反应,最终多器官功能衰竭。临床治疗中,早期稳定血流动力学、行血运重建是心源性休克的主要治疗方式。

尽管在血管重建策略和机械循环支持(MCS)设备方面取得了进展,但急性心肌梗死和心源性休克患者的死亡率仍然很高。为了阐明合并下肢外周血管疾病(PAD)与CS和AMI的结果之间的关系,来自哥伦比亚大学欧文医学中心/纽约长老会医院心脏病科的专家开展了相关研究,结果发表在JACC杂志上。

2015年10月1日至2018年6月30日住院的CS和AMI的医疗保险受益人中定义了PAD状态。到2018年12月31日确定的主要结果包括院内和院外的死亡率。次要结果包括出血、截肢、中风和下肢血管再造。对混杂因素进行调整的多变量回归模型被用来估计风险。亚组分析包括接受MCS治疗的患者和接受冠状动脉血运重建的患者。

在71690名患者中,5.9%(N = 4259)有PAD。平均年龄为77.8±7.9岁,58.7%为男性,84.3%为白人。累计院内死亡率为47.2%,总的来说,有PAD的患者死亡风险大50%(56.3% vs 46.6%;调整后的OR=1.50;95% CI:1.40-1.59)。

PAD患者的院内截肢(1.6% vs 0.2%;调整后的OR:7.0;95% CI:5.26-9.37)和院外死亡(67.9% vs 40.7%;调整后的HR:1.78;95% CI:1.67-1.90)的风险也分别高6倍和78%。此外,PAD患者较少使用机械循环辅助(21.5% vs 38.6%),并且与较高的死亡率、下肢血管再造的需要和截肢风险有关。研究结果在接受冠状动脉血运重建的患者中是一致的。

图形摘要总结

综上,在出现AMI和CS的患者中,PAD与较差的肢体结果和生存率有关。除了较低的机械循环辅助使用率外,那些接受MCS的PAD患者的死亡率、下肢血管再造和截肢率都有所增加。

 

参考文献:

Outcomes Associated With Peripheral Artery Disease in Myocardial Infarction With Cardiogenic Shock. J Am Coll Cardiol. 2022 Apr, 79 (13) 1223–1235

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1855052, encodeId=1c4c185505212, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 15 07:07:35 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326932, encodeId=292a1326932d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332179, encodeId=a27513321e983, content=<a href='/topic/show?id=88f9510800b' target=_blank style='color:#2F92EE;'>#心源性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51080, encryptionId=88f9510800b, topicName=心源性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593364, encodeId=c151159336451, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593556, encodeId=01b6159355604, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-09-15 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1855052, encodeId=1c4c185505212, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 15 07:07:35 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326932, encodeId=292a1326932d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332179, encodeId=a27513321e983, content=<a href='/topic/show?id=88f9510800b' target=_blank style='color:#2F92EE;'>#心源性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51080, encryptionId=88f9510800b, topicName=心源性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593364, encodeId=c151159336451, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593556, encodeId=01b6159355604, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1855052, encodeId=1c4c185505212, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 15 07:07:35 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326932, encodeId=292a1326932d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332179, encodeId=a27513321e983, content=<a href='/topic/show?id=88f9510800b' target=_blank style='color:#2F92EE;'>#心源性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51080, encryptionId=88f9510800b, topicName=心源性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593364, encodeId=c151159336451, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593556, encodeId=01b6159355604, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1855052, encodeId=1c4c185505212, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 15 07:07:35 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326932, encodeId=292a1326932d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332179, encodeId=a27513321e983, content=<a href='/topic/show?id=88f9510800b' target=_blank style='color:#2F92EE;'>#心源性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51080, encryptionId=88f9510800b, topicName=心源性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593364, encodeId=c151159336451, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593556, encodeId=01b6159355604, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1855052, encodeId=1c4c185505212, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 15 07:07:35 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326932, encodeId=292a1326932d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332179, encodeId=a27513321e983, content=<a href='/topic/show?id=88f9510800b' target=_blank style='color:#2F92EE;'>#心源性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51080, encryptionId=88f9510800b, topicName=心源性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593364, encodeId=c151159336451, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593556, encodeId=01b6159355604, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Mon Apr 04 06:07:35 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-04-04 mhm295

相关资讯

JACC:基于瑜伽的护理可以改善急性心梗患者预后

鉴于印度缺乏心脏康复(CR)计划,且全世界范围内的CR覆盖率都很低,因此迫切需要寻找廉价的替代性CR模型。本研究旨在通过一项多中心随机对照试验,评估以瑜伽为基础的CR(瑜珈护理)对主要心血管事件和自我

JAMA:2剂与3剂乙肝疫苗在导致急性心肌梗塞上没有差异

接受HepB-CpG疫苗与HepB-alum疫苗相比,并没有达到急性心肌梗死风险增加的统计标准。

BMJ: 我国17%急性心梗患者仍使在用硫酸镁!China PEACE研究全新分析

1991年公布的ISIS-4大规模临床试验结果推翻既往认知,提出静脉镁剂不仅对降低急性心肌梗死无益,甚至有害。自2000年起,国内外指南均不主张在急性心肌梗死患者中常规使用静脉镁。

JACC:皮下注射selatogrel可以抑制急性心梗患者血小板聚集

口服P2Y12受体拮抗剂对急性心肌梗死(AMI)患者血小板抑制有延迟作用。Selatogrel是一种高效、高选择性、可逆的P2Y12受体拮抗剂,起效快,作用时间短。本研究的目的旨在评估皮下注射Sela

JAHA:诊断左束支阻滞患者急性心梗的新心电图算法

目前的心电图算法对诊断左束支传导阻滞的急性心肌梗死(AMI)缺乏敏感性。

心梗的痛,到底是种什么样的痛?

心梗的痛一定要及时鉴别!

拓展阅读

没有典型心电图表现,上腹痛伴头痛竟是急性心梗

患者男性,61岁,因持续性上腹部疼痛伴头痛10小时于2023-08-07上午就诊。

术后死亡丨急性心梗前降支植入支架后对角支丢失,术后第2天凌晨患者猝死

患者男性,79岁,因反复黑便3天、胸痛和胸闷4小时急诊入院。

REDUCE-AMI研究结果发布! β-受体阻滞剂在急性心梗合并左室功能保留的患者未能获得长期获益 | ACC.24研究速递

研究者们设计了REDUCE-AMI研究,旨在明确急性心肌梗死合并左室功能保留的患者长期口服β-受体阻滞剂能否改善其预后。

恩格列净或可降低急性心梗后首次因HF住院发生风险,EMPACT-MI研究结果公布! | ACC.24研究速递

恩格列净属于钠-葡萄糖协同转运蛋白2抑制剂,用于2型糖尿病患者降低血糖,近年来也被认为其可降低HF事件的风险。EMPACT-MI是一项全球性临床研究,目的在于评价恩格列净在AMI中的有效性与安全性。

急性心梗回旋支支架术后半小时再闭塞又补了支架

① 介入手术无小事,优化技术是关键。② 充分抗栓,预防为主。③ 处处留心皆学问,注重临床基础。

2023年度巨献:中国中药领域十大医学研究出炉

2023年梅斯年终巨献:中国重磅级医学研究成果解读!